Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, AŞ Message Board

  • akos103 akos103 Jan 18, 2012 2:34 PM Flag

    Another buy rating, $20 target

    Canaccord Genuity Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR) on Continued Positive Script Trends and Aggressive Strategy



    E-mail Address
    More News related to OPTR
    Canaccord Genuity Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR) on Continued Positive Script Trends and Aggressive Strategy


    January 18, 2012 9:31 AM EST

    Canaccord Genuity reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $20.00.

    Canaccord analyst, George Farmer, said, "OPTR reported 2011 DIFICID gross sales of $24.4M, a total of $12.1M in Q3/11 (includes $5.1M to fully-stock inventory) and $12.2M in Q4/11, with strong Q4 m/m growth of ~11%. End of Q4/11 inventory decreased $1.1M, resulting in Q4/11 ex-wholesaler sales of $13.3M, a 90% increase compared to Q3/11 ex-wholesaler sales of $7M. This is reflected in an 87% increase between Q3 and Q4 of wholesale shipments from 2505 to 4675 treatments. DIFICID shipments to wholesalers in Q4/11 grew at an 11.3% compounded monthly growth rate. We now model for the Euro 50M Astellas milestone payment in Q2/12."

    SortNewest  |  Oldest  |  Most Replied Expand all replies